ReviewMaedica2026
The Prevalence and Risk of Polycystic Ovarian Syndrome (PCOS) in Women with Epilepsy: a Systematic Review and Meta-Analysis.
Review in Maedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Women with epilepsy suffer from a wide range of endocrine dysfunctions such as polycystic ovarian syndrome (PCOS). The literature shows various prevalence rates of PCOS in women with epilepsy/seizures. So, we designed this study to estimate the pooled prevalence of PCOS in women with epilepsy/seizures. Methods: PubMed, Scopus, EMBASE, Web of Science and Google Scholar were systematically searched by two independent researchers on March 1st 2023. Results: A literature search revealed 1377 records, of which 120 full-texts were evaluated and finally, 28 studies remained for the present systematic review. Most studies were from India, followed by Finland and Italy. A total of 2587 cases with epilepsy and 607 controls were evaluated. Studies were published between 1984 and 2022. The estimated pooled prevalence of PCOS in women with epilepsy was 19% [95% confidence interval (CI) 14-23%] (I2=91.7%, p<0.001). The estimated odds ratio of PCOS in women with epilepsy was 3.07 (95% CI 1.94-4.85) (I2=43.6%, p=0.07). The estimated prevalence of PCOS in women treated with valproic acid (VAL) was 32% (95% CI 20-45%) (I2=87.9%, P<0.001). Conclusion: The results of this systematic review show that the pooled prevalence of PCOS in women with epilepsy is 19% and the risk of developing PCOS is three-fold higher than in healthy women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.